DDInter554 DDInter1376
Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digitalis_ plant, studied by William Withering, an English physician and botanist in the 1780s.[A178237,A178240] Prior to this, a Welsh family, historically referred to as the _Physicians of Myddvai_, formulated drugs from this plant. They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Digoxin {u} (Compound) resembles {v} (Compound) Deslanoside
Digoxin {u} (Compound) resembles {v} (Compound) Acetyldigitoxin
Digoxin {u} (Compound) binds {v} (Gene) ATP1A3
Digoxin {u} (Compound) upregulates {v} (Gene) RRN3
Digoxin {u} (Compound) palliates {v} (Disease) dilated cardiomyopathy
Digoxin {u} (Compound) is included by {v} (Pharmacologic Class) Cardiac Glycosides
Digoxin {u} (Compound) downregulates {v} (Gene) C17orf62
Digoxin {u} (Compound) causes {v} (Side Effect) Thrombocytopenia
Digoxin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium oxide
Digoxin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticlopidine
Digoxin (Compound) resembles Deslanoside (Compound)
Digoxin (Compound) resembles Acetyldigitoxin (Compound)
Digoxin (Compound) binds ATP1A3 (Gene)
Digoxin (Compound) upregulates RRN3 (Gene)
Digoxin (Compound) palliates dilated cardiomyopathy (Disease)
Digoxin (Compound) is included by Cardiac Glycosides (Pharmacologic Class)
Digoxin (Compound) downregulates C17orf62 (Gene)
Digoxin (Compound) causes Thrombocytopenia (Side Effect)
Digoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Digoxin may cause a minor interaction that can limit clinical effects when taken with Ticlopidine